Fresenius SE & Co. (OTCMKTS:FSNUY) Short Interest Down 96.9% in August

Key Points

• Short interest plunged 96.9% in August to 32,056 shares from 1.03 million, leaving just 0.0% of shares short and a days-to-cover ratio of 0.2.
• Fresenius shares recently traded at $13.00, up 0.6%, with a $29.29 billion market capitalization. The company’s latest quarterly revenue of $6.91 billion exceeded estimates, although EPS of $0.24 narrowly missed expectations.
• Analysts remain positive, with Deutsche Bank and Morgan Stanley reiterating bullish ratings and all three tracked analysts assigning the stock a “Buy” consensus rating.

Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) saw a significant decrease in short interest in the month of August. As of August 31st, there was short interest totaling 32,056 shares, a decrease of 96.9% from the August 15th total of 1,029,832 shares. Based on an average daily trading volume, of 141,927 shares, the days-to-cover ratio is presently 0.2 days. Currently, 0.0% of the company's shares are short sold.

Fresenius SE & Co. Trading Up 0.6%

Shares of OTCMKTS FSNUY traded up $0.08 during trading on Thursday, reaching $13.00. The company had a trading volume of 70,269 shares, compared to its average volume of 150,275. The stock has a market cap of $29.29 billion, a P/E ratio of 16.46 and a beta of 0.62. The company's fifty day moving average price is $12.92 and its 200-day moving average price is $12.53. The company has a quick ratio of 0.98, a current ratio of 1.27 and a debt-to-equity ratio of 0.41. Fresenius SE & Co. has a 12 month low of $10.33 and a 12 month high of $33.93.

Fresenius SE & Co. (OTCMKTS:FSNUY - Get Free Report) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $0.24 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.25 by ($0.01). The company had revenue of $6.91 billion for the quarter, compared to the consensus estimate of $6.65 billion. Fresenius SE & Co. had a return on equity of 10.33% and a net margin of 6.67%. As a group, research analysts expect that Fresenius SE & Co. will post 1.08 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of Fresenius SE & Co. in a research report on Thursday, August 6th. Morgan Stanley restated an "overweight" rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Fresenius SE & Co. has a consensus rating of "Buy".

About Fresenius SE & Co.

Fresenius SE & Co KGaA is a Germany-based global health care company headquartered in Bad Homburg. The company develops and provides products and services for hospitals, outpatient care, and patients with chronic or complex medical conditions.

Its principal operating businesses are Fresenius Kabi and Fresenius Helios. Fresenius Kabi supplies medicines, clinical nutrition products, infusion and transfusion technologies, and related devices and services. Fresenius Helios operates hospitals and outpatient facilities, primarily in Germany and Spain, providing a broad range of medical and surgical care.

Fresenius traces its origins to a pharmacy established by the Fresenius family in Frankfurt in the 15th century and has evolved into an international health care group serving markets across Europe, North America, Latin America, Asia, and other regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.